Gen­mab takes a hit af­ter J&J sounds re­treat on can­cer com­bos, as pa­tient deaths force re­search­es to scrap tri­als

Roche’s re­port­ed suc­cess on lung can­cer to­day came af­ter an­oth­er set­back for their check­point Tecen­triq.

In­ves­ti­ga­tors at J&J were forced to scrap an ear­ly-stage com­bi­na­tion of the PD-L1 drug with their Gen­mab-part­nered Daraza­lex (dara­tu­mum­ab) for sec­ond-line lung can­cer cas­es af­ter it proved in­ef­fec­tive as well as pos­si­bly dan­ger­ous. And J&J went on to scrap an ear­ly-stage com­bi­na­tion study us­ing an in-house PD-1 with dara­tu­mum­ab for mul­ti­ple myelo­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER